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Abstract
Background: To quantify the financial cost of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc).
Methods: Healthcare use was captured through data linkage, wherein clinical data for SSc patients enrolled in the
Australian Scleroderma Cohort Study were linked with hospital, emergency department (ED) and ambulatory care
databases (MBS) for the period 2008–2015. PAH was diagnosed on right heart catheter according to international
criteria. Determinants of healthcare cost were estimated using logistic regression.
Results: Total median (25th–75th) healthcare cost per patient (including hospital, ED and MBS cost but excluding
medication cost) for our cohort during 2008–2015 was AUD$37,685 (18,144-78,811) with an annual per patient
healthcare cost of AUD$7506 (5273-10,654). Total healthcare cost was higher for SSc-PAH patients compared with
those without PAH with a total cost per patient of AUD$70,034 (37,222-110,814) vs AUD$34,325 (16,093 – 69,957),
p < 0.001 respectively with an annual excess healthcare cost per PAH patient of AUD$2463 (1973-1885), p < 0.001.
The cost of SSc-PAH occurs early post PAH diagnosis with 89.4% utilizing a healthcare service within the first 12
months post PAH diagnosis with an associated cost per patient of AUD$4125 (0–15,666). PAH severity was the main
significant determinant of increased healthcare cost (OR 2.5, p = 0.03) in our PAH cohort.
Conclusions: Despite SSc-PAH being a low prevalence disease, it is associated with significant healthcare resource
utilization and associated economic burden, predominantly driven by the severity of PAH.
Keywords: Systemic sclerosis, Scleroderma, Pulmonary arterial hypertension, Healthcare utilization and associated
direct cost, Economic Burden
Background
Systemic sclerosis (SSc) is a chronic multisystem auto-
immune disease characterized by vasculopathy and fi-
brosis [1] occurring with a worldwide prevalence of 7–
489/million and an incidence of 0.6–122/million/year
[1]. As there is no cure for SSc and few effective disease
modifying agents, SSc is associated with significant mor-
bidity, mortality and reduced health related quality of life
(HRQoL) [2]. Furthermore, SSc is associated with a sub-
stantial healthcare cost with an annual health service
utilisation cost per patient, including hospitalisations,
emergency care, ambulatory visits and medication use,
of AUD$11,607.07 (direct cost) [3], predominantly
driven by the presence of cardiopulmonary involvement
including pulmonary arterial hypertension (SSc-PAH)
and interstitial lung disease (SSc-ILD) [3–5].
SSc-PAH, occurring with a prevalence of 10–13% in
SSc [6, 7], is the leading cause of SSc-related mortality
[8], with a standardized mortality ratio (SMR) of 5.8
(95%CI 4.3–7.8) and 15.2 years of life lost (YLL) [9].
PAH is characterized by abnormal proliferation, vaso-
constriction and in-situ thrombosis of the pulmonary
vasculature, leading to elevated pulmonary vascular re-
sistance (PVR), resulting ultimately in right heart failure
and death [10]. Despite annual screening for PAH and
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the availability of specific PAH vasodilator therapies, the
median (25th–75th) survival time from PAH diagnosis is
only 4.0 (2.2–6.2) years [9]. Predictors of mortality in-
clude worse World Health Organization Functional
Class (WHO-FC), the presence of a pericardial effusion,
advancing age (> 60 years), male gender and a worse
hemodynamic profile at PAH diagnosis (defined by in-
creased mean pulmonary arterial pressure (PAP), right
atrial pressure (RAP) and PVR, and a reduced cardiac
index (CI)), while the use of combination PAH therapy
confers a survival advantage over monotherapy [9, 11].
In Australia, the government only subsidizes monother-
apy if prescribed by a physician in a government desig-
nated PAH treatment centre with combination therapy
occurring through hospital or pharmaceutical company
compassionate access, or at patients’ own expense.
Given the prevalence of SSc-PAH and its poor progno-
sis, it is surprising that studies on healthcare utilization
and associated economic burden specific to SSc-PAH
are scarce with only one retrospective cohort study
assessing all-cause healthcare cost in SSc patients with
lung involvement including only 108 SSc-PAH patients
[4]. Studies on healthcare utilization and associated cost
in general PAH, not specific to Group 1 PAH that en-
compasses SSc-PAH, are more prevalent and have
highlighted the importance of a point-in-time measure-
ment of the WHO-FC as a predictor of PAH progres-
sion, survival, healthcare utilization and associated cost
[12, 13]. One might therefore deduce that by improving
overall survival and reducing or maintaining WHO-FC
through the initiation of PAH specific therapy one might
alter the associated healthcare burden (predominantly
through reduced hospitalizations and ambulatory care
visits) and cost. However, this has only been reported in
a couple of studies preformed in the US in patients with
general PAH [14–16].
Therefore, we sought to quantify healthcare utilization
in SSc-PAH and its associated direct cost by means of data
linkage and to determine the presence, if any, of modifi-
able factors. Efficient usage of healthcare budgets is critical
for the maintenance of a sustainable healthcare system
and relies on economic studies, such as ours, to provide
real life cost figures to clinicians and health policy makers
to enable the appropriate allocation of resources and to
evaluate health policies and interventions.
Methods
Consecutive SSc patients from four Australian states
[Victoria (VIC), South Australia (SA), Western Australia
(WA) and Tasmania (TAS)] prospectively enrolled in
the Australian Scleroderma Cohort Study (ASCS), a
multi-center study of clinically important outcomes in
SSc, were included. The ASCS database collects compre-
hensive demographic and disease-related data on an
annual basis. Written consent was obtained from all pa-
tients at recruitment and ethical approval was obtained
from all participating hospitals (St. Vincent’s Hospital,
Melbourne, Monash Health, Royal Adelaide Hospital,
Royal Perth Hospital and Royal Hobart Hospital,
Tasmania).
Inclusion and exclusion criteria
We included all adult (≥18 years) SSc patients recruited in
the ASCS between January 2008 (cohort inception) and
December 2015 (when data linkage occurred). All patients
fulfilled the American College of Rheumatology / Euro-
pean League Against Rheumatism Classification criteria
for SSc [17]. To ensure that we only evaluated the cost as-
sociated with WHO Group 1 PAH in our SSc cohort, we
excluded those with Group 1 PAH and co-existing ILD
with a FVC < 70% and an abnormal high-resolution com-
puter tomography (HRCT) of the chest. Ventilation perfu-
sion scanning was preformed to exclude pulmonary
hypertension due to chronic thromboembolism.
ASCS clinical data
All ASCS patient undergo annual screening for PAH
and ILD with a transthoracic echocardiogram (TTE) and
respiratory function test (RFT). PAH was diagnosed by
right heart catheterization (RHC) according to inter-
national criteria [18]. Severe PAH was defined based on
presence of four of the following PAH severity criteria:
WHO-FC IV, pericardial effusion, six-minute walk dis-
tance (6MWD) < 300m, RAP on RHC of > 15mmHg and
CI of < 2 L/min/m2 [19]. Mild ILD was defined by charac-
teristic fibrotic changes on high-resolution computed
tomography (HRCT) lung (< 10% abnormal lung involve-
ment) and a forced vital capacity of > 70% on respiratory
function tests [17, 20]. Monotherapy is treatment with a
single PAH specific therapy (endothelin receptor antago-
nists (ERA), phosphodiesterase-5-inhibitors (PDE5) or
prostacyclin analogues) and was prescribed at the discre-
tion of the managing physician(s), while combination ther-
apy is treatment with more than one specific PAH agent
from different classes at one time. Patient status (alive or
dead) was censored in January 2016.
Data linkage
Healthcare utilization was captured by means of a com-
prehensive data linkage that we have previously de-
scribed [21].
Healthcare utilization and costing methodology
The method of calculating healthcare utilization and
costing has been previously described [21]. The most
common reasons for hospital admission were noted for
admissions lasting more than one day in order avoid in-
cluding recurring day admissions for example for
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intravenous infusions and haemodialysis. The cost of
PAH specific vasodilator therapies was calculated from
the PBS Dispensed Price for Maximum Quantity
(DPMQ) paid for the standard dose of each medication,
which is the cost the government contributes towards
each medication dispensed. However, this cost was not
included in the total healthcare cost calculation so as to
allow the equitable comparison of healthcare service use
in those with and without PAH. It is included as a Add-
itional file Table.
Statistical analysis
Data are presented as mean ± standard deviation (SD)
for normally distributed, median (25th–75th) for non-
normally distributed continuous variables, and as num-
ber (percentage) for categorical variables. Differences in
frequency were tested using chi-square and Fisher’s
exact tests. To determine the associations of different
PAH specific variables with healthcare utilization and as-
sociated cost univariable and multivariable logistic re-
gression were used. Variables with a p-value < 0.05 in
univariable regression or variables deemed to be of clin-
ical significance to the outcome with a p-value < 0.20
were included in the multivariable logistic regression
analysis. A subgroup analysis to determine healthcare
costs between those with and without PAH was pre-
formed using propensity score matching. A two-tailed p
value of 0.05 or less was considered statistically signifi-
cant. All statistical analyses were performed using
STATA 14.0 (StataCorp LP, College Station, TX, USA).
Results
Patient characteristics
Our study cohort consisted of 1128 SSc patients contrib-
uting 5527.2 person years of follow-up. Of these, 153
(13.6%) developed PAH over a mean follow-up of 4.6 ±
2.6 years with a mean age at diagnosis of 63.4 ± 10.4
years. PAH patients, compared with those without PAH,
were older at SSc onset (49.3 vs 45.7 years, p = 0.004)
with a longer disease duration (14.5 vs 10.6 years) and
were more likely to be anti-centromere antibody (ACA)
positive (50.3% vs 41.6%, p= 0.01), have digital ulcers (57.3%
vs 47.2%, p= 0.02), telangiectasia (92.2% vs 83.6%, p = 0.01)
and calcinosis (58.2% vs 39.9%, p < 0.001) (Table 1). Further-
more, they were more likely to be in WHO-FC III or IV
(86% vs 28.0%, p < 0.001), have a low 6MWD (289.6m vs
439.1m, p < 0.001) and have a history of angina (26.2% vs
12.0%, p < 0.001) (Table 1).
PAH patients were predominantly Caucasian (94.7%)
females (87.6%), with limited disease subtype (75.2%)
(Table 1). Of those with autoantibody data, 77 (50.3%)
were positive for ACA, 14 (9.2%) were
antitoposomerase-1 (Scl-70) positive and 12 (7.9%) were
RNA Polymerase III (RNAP) antibody positive (Table 1).
At the time of PAH diagnosis, the mean 6MWD was
329.3 ± 109.9 m, over three quarters of patients were in
WHO-FC III or IV (62.5% in WHO-FC III, 9.8% in
WHO-FC Class IV), 11.8% had a pericardial effusion
and 66% fulfilled the criteria for severe PAH (Table 2).
Survival in those with PAH was 4.8 ± 3.0 years from
PAH diagnosis (4.3 ± 2.7 years for those who died and
5.3 ± 3.3 years in those still alive at censorship) (Table 2).
One third of patients were treated with combination
PAH therapy with the remainder treated with monother-
apy (Table 2). PAH patients compared to those without
PAH were more likely to be prescribed an anticoagulant
and a diuretic (56.5% vs 19.9%, p < 0.001 and 29.9% vs
7.1%, p < 0.001).
Healthcare utilization and associated direct cost
Hospital admission and cost
Within our cohort, 81.8% of patients were admitted to
hospital at least once during 2008–2015, more com-
monly for patients with SSc-PAH compared with those
without PAH (92.2% vs 80.2%, p < 0.001). The annual
per patient median admission frequency was 5 (2–11)
and average length of stay (LOS) was 2.1 (1.1–4.1) days,
higher for those with SSc-PAH that those without (ad-
mission frequency 5 (3–10) vs 4 (2–11), p < 0.001 and
LOS 3.5 (1.8–4.9) vs 1.9 (1.1–1.9), p < 0.001 respectively).
The primary admission diagnosis for SSc-PAH patients
was PAH followed by heart failure, while for those with-
out PAH, a complication of their systemic sclerosis
followed by pneumonia were the most common reasons
for admission (Table 3).
The total hospital admission cost per patient for our
cohort during 2008–2015 was AUD$81,530 (42,637-175,
641) with a median (25th–75th) annual admission cost
per patient of AUD$3850 (2387-5981) (Table 4). These
costs were higher for SSc-PAH patients compared with
those without PAH with a total admission cost per pa-
tient of AUD$94,991 (56,866-178,464) vs AUD$79,052
(37,698 – 175,264), p < 0.001 and mean annual admis-
sion cost per patient of AUD$4802 (3344-6948) vs
AUD$3654 (2251-5737), p < 0.001 (Table 4).
PAH patients who died in close temporal proximity
with their hospital admission were admitted to hospital
more frequently than those without PAH (3.4 (2.3–5.9)
vs 2.3 (1.3–3.4), p = 0.001), had a higher LOS (4.3 (2.5–
6.3) vs 2.5 (1.2–4.3), p = 0.001) and higher admission
cost (AUD$5847.4 ± 3341.5 vs 4976.9 ± 2857.2, p = 0.05)
than those who survived.
ED presentation and cost
During 2008–2015, 65.1% of SSc patients presented to
the ED (79.7% with PAH vs 62.8% without PAH, p <
0.001) with an annual median per patient ED presenta-
tion of 2 (1–3) visits (Table 3). SSc-PAH patients had
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more frequent annual ED presentations than those with-
out PAH (2 (1–4) vs 2 (1–3), p < 0.001). The most com-
mon reason for ED presentation for those with SSc-PAH
was chest pain followed by dyspnea, while for those
without PAH, chest pain followed by abdominal pain
were the primary reasons for presentation (Table 3).
The total ED cost per patient for our cohort during
2008–2015 was AUD$3047 (1266 -5465), with a median
Table 1 Characteristics of SSc patients by PAH status
Patient characteristics
(n=1,128)
PAH No PAH p value
mean ± SD or n(%) mean ± SD or n(%)
Number of patients 153 (13.6%) 975 (86.4%)
Demographics
Age on SSc onseta, years 49.3 ± 13.9 45.7 ± 13.9 0.004
Disease duration at recruitment, years 14.5 ± 11.9 10.6 ± 9.9 <0.01
Female 134 (87.6%) 794 (81.4%) 0.06
Limited disease subtype 115 (75.2%) 684 (73.4%) 0.65
Caucasian Ethnicity 142 (94.7%) 839 (94.8%) 0.95
Follow-up, years 4.6 ± 2.6 4.9 ± 2.5 0.16
Alive at censorship 68 (44.4%) 707 (72.5%) <0.01
Autoantibody profile
Anti-centromere pattern ANA 77 (50.3%) 406 (41.6%) 0.01
Scl 70 +ve 14 (9.2%) 132 (13.5%) 0.02
RNA polymerase III +ve 12 (7.9%) 87 (8.9%) 0.07
Clinical manifestationsb
Digital ulcers ever 87 (57.3%) 440 (47.2%) 0.02
Telangiectasia ever 141 (92.2%) 815 (83.6%) 0.006
Calcinosis ever 89 (58.2%) 389 (39.9%) <0.01
GIT involvement 133 (86.9%) 802 (82.3%) 0.15
Renal Crisis 2 (1.3%) 31 (3.3%) 0.18
Pericardial Effusion 28 (41.3%) 124 (12.3%) <0.01
Mild ILD (FVC>70%) 42 (27.5%) 208 (21.3%) 0.09
6MWD 289.6 ±115.3 439.1 ± 118.2 <0.01
WHO Functional Class
Class I 2 (1.3%) 275 (30.6%) <0.01
Class II 19 (12.6%) 372 (41.4%)
Class III 83 (55.0%) 231 (25.7%)
Class IV 47 (31.1%) 21 (2.3%)
Brain Natriuretic Peptide 295 ± 140 84.9 ± 18.0 <0.01
N-terminal pro b-type
Natriuretic Peptide
1799 ± 1542 375 ± 110 0.03
Co-morbidities
Angina 32 (26.2%) 121 (12.0%) <0.01
CVA 7 (11.1%) 146 (13.7%) 0.56
Diabetes Mellitus 14 (15.7%) 139 (13.4%) 0.53
COAD 23 (16.5%) 130 (13.1%) 0.27
Current smoker 15 (10.4%) 138 (14.1%) 0.19
Abbreviations: pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), gastrointestinal tract (GIT), six minute walk distance (6MWD), world health
organization (WHO), health assessment questionnaire (HAQ), scleroderma HAQ (sHAQ), hypertension (HTN), cerebrovascular accident (CVA), peripheral vascular
disease (PVD), chronic obstructive airways disease (COAD)
adisease duration defined as from first non-Raynaud’s disease manifestation,
bclinical manifestations defined as present if ever present from SSc diagnosis
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(25th–75th) annual per patient ED presentation cost of
AUD$422 (0–748) (Table 4). Again, these costs were
higher for SSc-PAH patients compared with those with-
out PAH with a total ED cost per patient of AUD$3676
(2099-5699) vs AUD$2836 (1034 – 5279), p < 0.001 and
median (25th -75th) an annual ED cost per patient of
AUD$655 (421–1009) vs AUD$411 (0–718), p < 0.001
(Table 4).
MBS utilization and cost
The majority of patients in our cohort (95.8%) utilized a
MBS service during 2008–2015 (98.7% with PAH vs
95.4% without PAH, p = 0.05), with an annual median
per patient service utilization of 76 (47–125) MBS ser-
vices (Table 3). SSc-PAH patients utilized more MBS
services annually than those without PAH (108 (71–162)
vs 69 (43–113), p < 0.001). The most commonly utilized
MBS services in those with and without PAH were iden-
tical with the primary services being pathology followed
by medical professional visits (Table 3). Furthermore,
the allied health services utilized by those with and with-
out SSc-PAH were identical with podiatry being the
most frequently utilized service followed by nurse
wound care, physiotherapy and psychology sessions.
The total MBS cost per patient for our cohort during
2008–2015 was AUD$23,568 (15,987-35,111), with a
median (25th -75th) annual per patient MBS cost of
AUD$2426 (1455-3734) (Table 4). Again, these costs
were higher for SSc-PAH patients compared with those
without PAH with a total MBS cost per patient of
AUD$27,531(19,493-39,738) vs AUD$22,861(15,359-33,
842), p < 0.001 and median (25th -75th) annual MBS
cost per patient of AUD$3289 (2337-4752) vs
AUD$2288 (1366-3503), p < 0.001 (Table 4).
Total healthcare utilization and associated cost
The total healthcare cost (including hospital, ED and
MBS cost but excluding medication cost) for our cohort
during 2008–2015 was AUD$37,685 (18,144-78,811)
with an annual per patient healthcare cost of AUD$7506
(5273-10,654). Total healthcare cost was higher for SSc-
PAH patients compared with those without PAH with a
total cost per patient of AUD$70,034 (37,222-110,814)
vs AUD$34,325 (16,093 – 69,957), p < 0.001, and median
(25th -75th) annual healthcare cost per patient of
AUD$9612 (6931-12,086) vs AUD$7149 (4958-10,201),
p < 0.001 (Table 4). In our subgroup analysis, PAH pa-
tients incurred an annual healthcare cost of
AUD$1199.42 (95%CI 355.3–2043.5, p = 0.005) more
than those without PAH matched for age at SSc onset,
gender, ethnicity, disease subtype and the presence of
DU, telangiectasia and calcinosis.
Total healthcare utilization and cost in SSc-PAH
Within three months of PAH diagnosis, over half of the
SSc-PAH patients (53.3%) had utilized a healthcare ser-
vice (26.7% had been admitted to hospital, 13.3% had
presented to the ED and 53.3% had utilized a MBS ser-
vice). The median cost per patient associated with these
healthcare services was AUD$1123 (0–5383); the major-
ity of the cost was related to hospitalizations followed by
MBS service utilization. Within six months of PAH diag-
nosis, two-thirds of the SSc-PAH patients (66.3%) had
utilized a healthcare service (30.5% had been hospital-
ized, 39.1% had presented to the ED department and
60.9% had utilized a MBS service). The median cost per
patient for these services was AUD$2337 (0–9268).
Table 2 Characteristics at PAH diagnosis
Patient characteristics at
PAH diagnosis
mean ± SD or n(%) p-value
Demographics
Age at PAH diagnosis, years 63.4 ± 10.4
Disease duration at PAH
diagnosisa, years
14.1 ± 11.6
WHO Functional Class at diagnosis
Class I 6 (4.5%)
Class II 32 (2.4%)
Class III 82 (62.5%)
Class IV 13 (9.8%)
Hemodynamic measurements at PAH diagnosis
6MWD,m 329.3 ±109.9
mRAP, mmHg 7.9 ± 3.8
mPAP, mmHg 33.9 ± 10.9
PAWP, mmHg 10.9 ± 4.0
mCI, L/min/m2 2.9 ± 1.3




Mean DLCO 48.9 ± 15.5
Mean DLCO/VA, % predicted
mL/min/mmHg
58.5 ± 19.6
Severe PAHb 101 (66.0%)
Overall survival 4.8 ± 3.0 0.04
Time to death from PAH diagnosis,
years(n=77)
4.3 ± 2.7
Survival from PAH diagnosis, years
(n=68)
5.3 ± 3.3
Abbreviations: pulmonary arterial hypertension (PAH), six minute walk distance
(6MWD), mean pulmonary arterial pressure (mPAP), mean right atrial pressure
(mRAP), pulmonary vascular resistance (PVR), cardiac index (CI), pulmonary
arterial wedge pressure (PAWP), diffusing capacity of the lungs for carbon
monoxide (DLCO), DLCO divided by the alveolar volume (DLCO/VA), world
health organization (WHO)
adisease duration defined as from first non-Raynaud’s disease manifestation,
bsevere PAH defined by the presence of WHO Functional Class IV, presence of
a pericardial effusion, 6MWD <300m, right atrial pressure on right heart
catheter of >15 and cardiac index of <2.
Morrisroe et al. BMC Pulmonary Medicine          (2019) 19:226 Page 5 of 11
Table 3 Healthcare utilisation in SSc by PAH status between 2008-2015
Characteristics per patient Overall
n (%) or mean±SD
Median (IQR)
PAH
n (%) or mean±SD
Median (IQR)
No PAH




Patient number 923 141 782
% of patients admitted to hospital 923/1128 (81.8%) 141/153 (92.2%) 782/975 (80.2%) <0.001
Median admissions per patient
(2008-2015)
5 (2-11) 5 (3-10) 4 (2-11) <0.001
Median annual hospital
admissions per patient
3.2 ± 6.4 4.4 ± 6.2 2.9 ± 6.4 <0.001
Mean annual 1.7 (1-3.3) 3 (1.7-4.5) 1.6 (1-3)
Average LOS per patient per admission 2.1 (1.1-4.1) 3.5 (1.8-4.9) 1.9 (1.1-1.9) <0.001
3.1 ± 3.1 3.9 ± 3.3 2.9 ± 3.1
Reason for admissiona
1. Systemic sclerosis(10.9%) PAH (9.7%) Systemic sclerosis (7.8%)
2. Pneumonia (5.4%) Heart Failure (6.4%) Pneumonia (5.2%)
3. PVD (4.5%) Pneumonia (4.6%) PVD (3.7%)
4. Heart Failure (2.5%) Systemic sclerosis Iron deficiency anaemia
5. Iron deficiency anaemia (4.1%) (2.4%)
(1.6%) Acute LRTI (2.3%) Chronic ulcer (1.4%)
Emergency Department Presentations
Patient number 734 122 612
% of patients presenting to ED 734/1128 (65.1%) 122/153 (79.8%) 612/975 (62.8%) <0.001
Median presentation per patient
(2008-2015)
7 (3-12) 9 (5-14) 6 (2-12) <0.001
Mean number 8.9 ± 7.7 10.0 ± 6.8 8.6 ± 7.9 <0.001
Median annual presentations per patient 2 (1-3) 2 (1-4) 2 (1-3) <0.001
Mean annual presentations per patient 2.6 ± 2.0 3.1 ± 2.3 2.5 ± 1.9 <0.001
Top 5 reasons for ED presentation
1. Chest pain (4.5%) Chest pain (4.9%) Chest pain (4.3%)
2 Dyspnoea (2.5%) Dyspnoea (3.8%) Abdominal pain (2.6%)
3. Abdominal pain (2.4%) Acute LRTI (3.6%) Dyspnoea (2.1%)
4. Acute LRTI (2.2%) Lobar pneumonia (3.4%) Acute LRTI (1.8%)
5. Lobar pneumonia (2.1%) Intestinal obstruction (2.8%) Lobar pneumonia (1.8%)
Medical Benefit Schedule (MBS)
Patient number 1,081 151 930
% of patients utilizing an MBS service 1,081/1,128 (95.8%) 151/153 (98.7%) 930/975 (95.4%) 0.05
Median services utilized per
patient (2008-2015)
557 (378-863) 761 (512-1,116) 523 (352-1116) <0.001
Mean number 670.2 ± 451.6 873.9 ± 502.6 623.4 ± 425.5 <0.001
Median annual MBS services
utilized per patient
76 (47-125) 108 (71-162) 69 (43-113) <0.001
Mean annual MBS services
utilized per patient
68.5 ± 56.9 100.9 ± 61.8 63.3 ± 54.4 <0.001
Top 5 MBS services utilized
1. Pathology (42.9%) Pathology (47.8%) Pathology (41.8%)
2. Professional visit (30.1%) Professional visit Professional visit (30.8%)
3. Allied Health (14.2%) (26.9%) Allied Health (14.2%)
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Hospitalizations were again the predominant driver of
these costs followed by MBS service utilization (Table 5).
By 12months after PAH diagnosis, 89.4% of SSc patients
had utilized a healthcare service (45.6% hospitalized,
40.9% presented to ED and 87.9% had utilized a MBS ser-
vice) with a median cost per PAH patient of AUD$4125
(0–15,666). By 24months post PAH diagnosis, all patients
had utilized a healthcare service with a median cost per
patient of AUD$11,856 (2529-28,968) with hospital ad-
missions being the predominant driver of costs. Health-
care costs for 3, 4 and 5 years post PAH diagnosis
followed a similar pattern and are summarized in Table 5.
The total per patient medication cost associated with the
use of PAH specific vasodilator therapy between 2008 and
2015 was AUD$53,842 (18,728-100,882) and is summa-
rized in Additional file 1: Table S1.
Determinants of above median total annual healthcare
cost (and its components excluding medication cost) as-
sociated with SSc-PAH by univariate logistic regression
are summarized in Additional file 1: Table S2. By multi-
variable logistic regression, severity of PAH (encompass-
ing WHO-FC) was the only determinant of total annual
healthcare cost in SSc-PAH patients (OR 2.5, p = 0.03)
(Table 6). After excluding medication costs, combination
PAH specific therapy did not significantly impact health-
care cost compared with monotherapy alone. Determi-
nants of each component of this healthcare cost in SSc-
PAH were also assessed. In multivariable logistic regres-
sion, female gender (OR 3.1, p = 0.05) and the presence
of severe PAH (OR 2.3, p = 0.04) were associated with an
above median annual hospital admission cost, while the
presence of COAD (OR 5.4, p = 0.03) was associated
Table 3 Healthcare utilisation in SSc by PAH status between 2008-2015 (Continued)
Characteristics per patient Overall
n (%) or mean±SD
Median (IQR)
PAH
n (%) or mean±SD
Median (IQR)
No PAH
n (%) or mean±SD
Median (IQR)
p-value
4. Diagnostic imaging (5.4%) Allied Health (14.1%) Diagnostic imaging (5.5%)
5. Therapeutic procedures (4.4%) Diagnostic imaging (4.9%) Therapeutic procedures (4.5%)
Therapeutic procedures (3.9%)
Abbreviations: medical benefits schedule (MBS), length of stay (LOS), emergency department (ED), lower respiratory tract infection (LRTI), pulmonary arterial
hypertension (PAH), peripheral vascular disease (PVD), patient (pt)
athese hospital admissions are the most frequent admission diagnosis for admissions lasting more than one day in order avoid including recurring day admissions
for intravenous infusions and haemodialysis
Table 4 The economic burden associated with healthcare utilization in SSc by PAH status











Total admission cost per patient (2008-2015) 81,530 (42,637-175,641) 94,991 (56,866-178,464) 79,052 (37,698 – 175,264) <0.01
Mean annual admission cost per patient 4,730 ± 4,348 5,405 ± 3,144 4,609 ± 4,522 <0.01
Median annual admission cost per patient 3,850 (2,387-5,981) 4,802 (3,344-6,948) 3,654 (2,251-5,737) <0.01
Emergency Department
Total ED cost per patient (2008-2015) 3,047 (1,266-5,465) 3,676 (2,099-5,699) 2,836 (1,034-5,279) <0.01
3823 ± 3349 4,234 ± 2,880 3,718 ± 3,451 <0.01
Mean annual ED cost per patient 531 ± 663 874 ± 900 477 ± 600 <0.01
Median annual ED cost per patient 422 (0-748) 655 (421-1,009) 411 (0-718) <0.01
Medical Benefit Schedule (MBS)
Total MBS cost per patient (2008-2015) 23,568 (15,987 – 35,111) 27,531 (19,493-39,738) 22,861 (15,359-33,842) <0.01
Mean annual MBS cost per patient 3,038 ± 2,720 4,056 ± 3,175 2,878 ± 2,607 <0.01
Median annual MBS cost per patient 2,426 (1,455-3,734) 3,289 (2,337-4,752) 2,288 (1,366-3,503) <0.01
Total healthcare cost
Total cost between 2008-2015 37,685 (18,144-78,811) 70,034 (37,222-110,814) 34,325 (16,093-69,957) <0.01
Mean total cost 60,855 ± 70,147 90,394 ±76,832 56,220 ± 67,925 <0.01
Mean annual cost per patient 8,635 ±5,591 10,227 ± 5,024 8,336 ±5,642 <0.01
Median annual cost per patient 7,506 (5,273-10,654) 9,612 (6,931-12,086) 7,149 (4,958-10,201) <0.01
Abbreviations: medical benefits schedule (MBS), emergency department (ED), pulmonary arterial hypertension (PAH)
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with an increased ED presentation cost; no specific fac-
tors were associated with increased annual MBS cost
(Table 6). Furthermore, worse WHO-FC was associated
with increasing total healthcare cost predominantly
driven by hospitalization cost (Additional file 1 Table
S3).
Discussion
This large well-characterized linkage study, including
153 SSc-PAH patients, investigates the healthcare bur-
den associated with SSc-PAH in SSc patients prospect-
ively enrolled in an Australian SSc cohort database
linked with hospital, ED and ambulatory care service da-
tabases. In our cohort of 1128 SSc patients, the preva-
lence of SSc-PAH was 13.6% over a mean follow-up of
4.6 ± 2.6 years, which is consistent with the literature
[22]. SSc-PAH patients utilized significantly more
healthcare resources, including hospitalization, ED pres-
entation and ambulatory care services, than those with-
out PAH. PAH patients were admitted to hospital
annually on average 1.5 times more than those without
PAH (p < 0.001), with the primary reason for admission
being their PAH; PAH patients had a longer LOS than
those without PAH (3.5 vs 1.9 days, p < 0.001). Similarly,
SSc-PAH patients presented to the ED more frequently
and utilized more ambulatory care services on an annual
basis than those without PAH (3.1 vs 2.5, p < 0.001 and
108 vs 69, p < 0.001 respectively). Use of healthcare ser-
vices overall, excluding medication cost, was associated
with an annual excess cost per SSc-PAH patient of
AUD$1891 ± 618, p < 0.001, predominantly driven by
hospital admission costs, with an annual excess cost per
SSc-PAH patient of AUD$796 ± 1378, p < 0.001. The
cost associated with SSc-PAH occurs early post PAH
diagnosis, with 66.3% of patients utilizing a healthcare
service within the first six months following diagnosis,
with an associated cost per patient of AUD$2337 (0–
9268); 89.4% utilizing a healthcare service within the first
12 months post PAH diagnosis with an associated cost
per patient of AUD$4125 (0–15,666). Severity of PAH
was the main determinant of increased healthcare cost
(OR2.5, p = 0.03) in our PAH cohort. Combination PAH
specific therapy did not significantly impact healthcare
cost compared with monotherapy alone.
In comparison with a US based SSc-PAH cohort (n =
108), who captured their PAH cohort retrospectively in
a healthcare claims database between 2003 and 2014 by
the International Classification of Disease-9-Clinical
Modification diagnosis codes on medical claims [4], our
SSc-PAH patients utilized more healthcare services with
a higher percentage of patients being hospitalized by five
years post PAH diagnosis (100% vs 64%). However, the
total hospitalization cost was significantly lower for our
SSc-PAH cohort (AUD$35,573 ± 41,154 (USD$24,537 ±
28,386) vs USD$40,957 ± 90,855). In terms of ED presen-
tations, 78.3% of our SSc-PAH patients had presented to
the ED by five years post diagnosis, which is similar to
72% reported in this US SSc-PAH cohort [4]. Again, our
total ED presentation cost over this five-year period fol-
lowing PAH diagnosis was lower than this US cohort
Table 5 Per patient annum average healthcare cost (AUD$) from PAH diagnosis












1st year of diagnosis
mean cost 11,016 ± 22,971 283 ± 626 3,019 ± 4,626 14,319 ± 27,040
median cost 1,008 (0-11,133) 0 (0-374) 2,458 (0-3,979) 4,125 (0-15,666)
2nd year of diagnosis
mean cost 7,240 ± 18,511 222 ± 453 2,190 ± 2,337 9,653 ± 19,833
median cost 0 (0 – 4,766) 0 (0-360) 1,740 (416-3,168) 2,737 (668 – 8,924)
3rd year of diagnosis
mean cost 6,002 ± 12,527 291 ± 640 2,029 ± 2,068 8,324 ± 13,748
median cost 0 (0-6,204) 0 (0-384) 1,554 (210 – 3,144) 3,579 (429-9,486)
4th year of diagnosis
mean cost 6,233 ± 13,729 199 ± 379 1,904 ± 2,156 8,336 ± 14,871
median cost 0 (0-6,962) 0 (0-384) 1,373 (0-2,988) 2,446 (0-10,980)
5th year of diagnosis
mean cost 5,080 ± 11,575 178 ± 433 1,890 ± 2,402 7,149 ± 12,903
median cost 0 (0-1,681) 0 (0-0) 1,178 (0-2,908) 1,755 (0-6,602)
Abbreviations: pulmonary arterial hypertension (PAH), emergency department (ED) Medical Benefit Schedule (MBS), standard deviation (SD), interquartile
range (IQR)
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(AUD$1175 ± 1456 (USD$810 ± 1004) vs USD$2987 ±
10,736). In terms of ambulatory care services, 100% of
SSc-PAH patients in both cohorts had utilized an ambu-
latory care service at five years post PAH diagnosis with
comparable total ambulatory care costs of AUD$11,
034 ± 8719 (USD$7610 ± 6014) vs USD$8232 ± 5260).
Similarly, the mean overall healthcare cost five years
post PAH diagnosis was lower for our cohort at
AUD$47,783 ± 46,081 (USD$32,959 ± 31, 785) vs
(USD$63,320 ± 98,531). This discrepancy in total health-
care cost is likely related to the exclusion of medication
cost in our cohort, which if included would add approxi-
mately an additional annual cost per patient of AUD$35,
076 (USD$24,198) for monotherapy and AUD$35,938
(USD$24,788) for combination PAH therapy, making the
total healthcare cost figures more comparable. Addition-
ally, our healthcare cost figures exclude the cost of out-
patient public hospital clinic appointments as the cost of
these clinics are not standardized across hospitals and
could not be included in the linkage.
Similar to our cohort, over half (57%) of those with
WHO Group 1 PAH included in the REVEAL registry of
US patients recruited between 2006 and 2009 [23], were
admitted to hospital with the main predictor of hospital-
izations being PAH severity. Congestive cardiac failure
(CCF) followed by the placement or removal of a central
venous catheter were the most common reasons for
hospitalization in the REVEAL registry, comparable to
the reasons for hospitalization in our SSc-PAH cohort
(PAH followed by CCF). Hospitalization was a predictor
of future hospitalization and mortality, with only 25.4%
of the REVEAL cohort remaining hospital free over a 3-
year follow-up period [23]. The association of
hospitalization and increased risk of death has been re-
ported previously in PAH patients [24] and has been re-
cently included as a variable in the updated REVEAL
risk score calculator used to predict clinical worsening
and survival in PAH patients [25].
The number of hospital admissions in our SSc-PAH
cohort was higher than that of a US based general PAH
patient cohort [12], with a mean of 0.4 hospitalizations
and a mean LOS of 0.3 days per patient per month
(pppm) in our cohort compared with 0.1 hospitaliza-
tions/ pppm and a mean average LOS of 1.0 days/pppm
which may reflect the underling severe nature and poor
prognosis of SSc-PAH relative to other causes of PAH
[11] in addition to the advanced age with increasing
numbers of co-morbidities. Interestingly, ED presenta-
tions among our SSc-PAH cohort were lower than re-
ported in the general PAH cohort with 0.2 ED visits/
pppm compared with 0.4 visits/pppm in the general
PAH cohort. For PAH cohorts, the average total health-
care cost is in the range of USD$2023–$9295 pppm de-
pending on how PAH was captured (US claims database,
transthoracic echocardiogram or RHC) and whether or
not PAH specific medication was included in the study
[14, 26–29]. Our cohort costs (AUD$852/pppm
(USD$587) are not comparable to these studies as we
have a very stringently defined SSc-PAH cohort, all diag-
nosed on RHC, and our total healthcare costs are
Table 6 Determinants of above median annual total healthcare
cost and its components in SSc-PAH in multivariable logistic
regression
Determinants of annual total healthcare cost OR (95%CI) p-value
Female 2.42 (0.8-7.6) 0.13
Age at onset of PAH, years 1.00 (0.9-1.0) 0.76
Caucasian ethnicity 2.89 (0.4-19.3) 0.27
Diffuse disease subtype 1.74 (0.7-4.5) 0.26
Digital ulceration 1.82 (0.8-3.9) 0.13
Mild ILD^ (FVC>70%) 1.63 (0.8-3.6) 0.23
Combination PAH specific therapy 1.01 (0.5-2.2) 0.97
Severe PAH* 2.46 (1.1-5.6) 0.03
Determinants of hospital cost OR (95%CI) p-value
Female 3.08 (0.9-9.7) 0.05
Caucasian ethnicity 1.94 (0.4-10.2) 0.43
Diffuse disease subtype 1.38 (0.6-3.4) 0.49
Severe PAH* 2.25 (1.1-5.0) 0.04
Mild ILD^ (FVC>70%) 1.97 (0.9-4.3) 0.09
Combination PAH specific therapy 1.35 (0.6-2.8) 0.43
Determinants of ED cost OR (95%CI) p-value
Female 1.38 (0.4-5.1) 0.62
Age at onset of PAH, years 1.00 (0.9-1.1) 0.72
Caucasian ethnicity 1.52 (0.2-10.6) 0.67
Diffuse disease subtype 1.26 (0.5-3.3) 0.64
Severe PAH* 1.61 (0.6-4.0) 0.31
COAD 5.44 (1.2-25.6) 0.03
Combination PAH specific therapy 0.65 (0.3-1.5) 0.31
Determinants of MBS cost OR (95%CI) p-value
Female 1.67 (0.6-4.8) 0.34
Age at onset of PAH, years 1.01 (0.9-1.1) 0.47
Caucasian ethnicity 6.89 (0.8-60.3) 0.08
Diffuse disease subtype 1.49 (0.6-3.5) 0.35
Severe PAH* 1.02 (0.5-2.1) 0.96
Combination PAH specific therapy 1.57 (0.8-3.2) 0.22
Abbreviations: pulmonary arterial hypertension (PAH), interstitial lung disease
(ILD), chronic obstructive airway disease (COAD), forced vital capacity (FVC),
emergency department (ED) Medical Benefit Schedule (MBS),
^ to ensure that we were only evaluating WHO Group 1 PAH in our SSc
cohort, patients were excluded if they had Group 1 PAH and co-existing ILD
with a FVC <70% and an abnormal high-resolution computer tomography
(HRCT) of the chest. V/Q scanning was preformed to exclude pulmonary
hypertension due to chronic thromboembolism
*severe PAH defined by the presence of WHO Functional Class IV, presence of
a pericardial effusion, 6MWD <300m, right atrial pressure on right heart
catheter of >15 and cardiac index of <2.
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deliberately exclusive of PAH specific therapies to allow
the cost disparity in terms of healthcare utilization be-
tween those with and without PAH to be equitable.
Strengths of our study include its well-characterized
SSc-PAH population, all fulfilling the ACR/EULAR cri-
teria for SSc [17], followed over a substantial time frame
and PAH being diagnosed on RHC according to inter-
national criteria [18]. Our study is also strengthened by
its linkage methodology which allows the real world reli-
able calculation of healthcare utilization and associated
cost to the Australian government. Study limitations in-
clude the possibility of underestimating the cost associ-
ated with PAH managed primarily in the public hospital
system as our data linkage methodology did not include
the cost of public outpatient clinics nor did we did cap-
ture the cost of any.
privately funded allied health service not covered by
the MBS. Furthermore, medication compliance was not
verified in this study potentially causing a slight over es-
timate of medication costs if medications recorded in
the database were not dispensed.
Conclusions
Despite SSc-PAH being a low prevalence disease, it is as-
sociated with significant healthcare resource utilization
and associated economic burden predominantly driven
by the severity of PAH. Our study highlights the need to
identify more effective therapeutic strategies to improve
disease progression and management of this costly
disease.
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